Skip to main content

Sarepta Therapeutics Shares Buoyed by RBC Upgrade

Analysts say the Duchenne muscular-dystrophy treatment could be a "major game changer" for Sarepta Therapeutics.

Sarepta Therapeutics (SRPT) - Get Sarepta Therapeutics, Inc. Report shares were boosted Tuesday by analysts with RBC Capital Markets. The team at RBC upgraded the stock to OUTPERFORM from SECTOR PERFORM, based on the accelerated FDA approval of its Duchenne muscular-dystrophy treatment, which analysts say could be a "major game changer." Sarepta shares have more than doubled over the past month, following a challenging start of 2016 for the drugmaker.

Employees of TheStreet are restricted from owning individual securities.

TheStreet Recommends